caa a22 4500 477058000 CHVBK 20180405111352.0 cr unu---uuuuu 170330e19960101xx s 000 0 eng 10.1007/BF00226334 doi (NATIONALLICENCE)springer-10.1007/BF00226334 Increase in magnesium plasma level after orally administered trimagnesium dicitrate [Elektronische Daten] [C. Wilimzig, R. Latz, W. Vierling, E. Mutschler, T. Trnovec, S. Nyulassy] Magnesium plasma concentrations were measured in healthy probands before and after administration of trimagnesium dicitrate by the oral and intravenous routes. There was a notable circadian fluctuation of the plasma concentration with a peak in the evening hours. After oral administration of 12 and 24 mmol magnesium, a long-lasting, statistically significant increase in plasma magnesium concentration measured as the increase in area under the curve (AUC) between 0 and 12 h, of 3.1% and 4.6%, respectively, was found. After intravenous administration of 4 and 8 mmol magnesium, AUCs increased by 9.5% and 16.1%, respectively. The decline in the plasma magnesium concentration after i.v. administration was compatible with a three-compartment model with a terminal half-time of about 8 h. Although no absolute value of the oral bioavailability of trimagnesium dicitrate could be determined from the data, our results may be important in helping to elucidate the influence of magnesium preparations on the plasma magnesium concentration. By comparing the effects of different preparations, it should be possible to estimate the relative oral bioavailability and the bioequivalence of these preparations. Springer-Verlag, 1996 Magnesium nationallicence Plasma level nationallicence pharmacokinetics nationallicence bioavailability nationallicence circadian fluctuation nationallicence Wilimzig C. Datapharm GmbH, Planegg, Munich, Germany aut Latz R. Datapharm GmbH, Planegg, Munich, Germany aut Vierling W. Pharmacological Institute, Technical University of Munich, Biedersteiner Strasse 29, D-80802, Munich, Germany aut Mutschler E. Pharmacological Institute, University of Frankfurt, Biocenter Niederusel, Frankfurt am Main, Germany aut Trnovec T. Institute for Preventive and Clinical Medicine, University of Bratislava, Slovak Republic aut Nyulassy S. Institute for Preventive and Clinical Medicine, University of Bratislava, Slovak Republic aut European Journal of Clinical Pharmacology Springer-Verlag 49/4(1996-01-01), 317-323 0031-6970 49:4<317 1996 49 228 https://doi.org/10.1007/BF00226334 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00226334 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Wilimzig C. Datapharm GmbH, Planegg, Munich, Germany aut NATIONALLICENCE 700 1- Latz R. Datapharm GmbH, Planegg, Munich, Germany aut NATIONALLICENCE 700 1- Vierling W. Pharmacological Institute, Technical University of Munich, Biedersteiner Strasse 29, D-80802, Munich, Germany aut NATIONALLICENCE 700 1- Mutschler E. Pharmacological Institute, University of Frankfurt, Biocenter Niederusel, Frankfurt am Main, Germany aut NATIONALLICENCE 700 1- Trnovec T. Institute for Preventive and Clinical Medicine, University of Bratislava, Slovak Republic aut NATIONALLICENCE 700 1- Nyulassy S. Institute for Preventive and Clinical Medicine, University of Bratislava, Slovak Republic aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 49/4(1996-01-01), 317-323 0031-6970 49:4<317 1996 49 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer